

Prescient Therapeutics Receives Two US Patents Covering PTX-200

Highlights:

- **PTX expands patent portfolio covering PTX-200 for breast cancer and leukemia**
- **Bolsters strong intellectual property position in a unique targeted therapy**

MELBOURNE Australia, 17 June 2020 – Prescient Therapeutics (ASX: PTX), a biotechnology company developing targeted and personalised medicines for cancer, is pleased to announce that it has received notices of allowance from the United States Patent and Trademark Office (USPTO) for two new patents covering its PTX-200 candidate for the treatment of leukemia and breast cancer. Once granted, the patents are expected to be valid until at least 2025.

Prescient CEO and Managing Director, Steven Yatomi-Clarke said, “We are very pleased with the overall progress of PTX-200. Early clinical data has been strong and underlines the potential of PTX-200 as a unique targeted therapy. The allowance of two additional US patents for PTX-200 is another important step in building out a strong product pipeline of novel personalised therapies for cancer. Prescient’s pipeline has never been stronger, nor deeper.”

“The first half of CY2020 has been tremendously exciting for Prescient. Despite COVID-19 disruptions we have made progress with our in-house targeted cancer therapy drugs (PTX-100 and PTX-200) and, through the recent announcement of our exciting OmniCAR platform, Prescient is at the forefront of most exciting and promising field in oncology.”

PTX-200 Patents

PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt, while being comparatively safer. This promising compound has encouraging Phase 2a data in HER2-negative breast cancer; Phase 1b/2 in relapsed and refractory AML and Phase 1b in ovarian cancer.



The PTX-200 patents (USPTO 15/487,854 and 15/487,843, entitled "Compositions of triciribine and epidermal growth factor receptor inhibitor compounds or salts thereof and methods of use thereof") are important additions to Prescient's strong intellectual property portfolio and will further enhance its protection of PTX-200 and its potential use in combination with a number of established chemotherapies therapies for a range of hard to treat cancers.

The PTX-200 Phase 1b study in patients with relapsed and refractory acute myeloid leukemia continues in the US after it was expanded on the back of positive clinical data showing a third complete response (total eradication of the disease) in a patient with this difficult to cancer. Researchers are working to identify the optimal dose of PTX-200 in combination with chemotherapy to minimise side effects.

Interim data from a Phase 1b safety study of PTX-200 in women with recurrent or persistent platinum resistant ovarian cancer showed 80 per cent (12 of 15) of patients exhibited 'disease control', with 11 women exhibiting stable disease and one having a partial response.

In December, data from the Phase 2a trial of PTX-200 in 11 women with HER-2 negative breast cancer showed an overall response rate of 91 per cent, with nine of 10 patients being monitored for cancer remaining progression-free, with encouraging ongoing durability of response.

– Ends –

About Prescient Therapeutics Limited (Prescient)

Prescient Therapeutics is a clinical stage oncology company developing personalised medicine approaches to cancer, including targeted and cellular therapies.

Cell Therapies

OmniCAR: is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. OmniCAR's modular CAR system decouples antigen recognition from the T-cell signalling domain. It is the first universal immune receptor allowing post-translational covalent loading of binders to T-cells. OmniCAR is based on technology licensed from Penn; the SpyTag/SpyCatcher binding system licensed from Oxford University; and other assets.

The targeting ligand can be administered separately to CAR-T cells, creating on-demand T-cell activity post infusion and enables the CAR-T to be directed to an array of different tumour antigens.

OmniCAR provides a method for single-vector, single cell product targeting of multiple antigens simultaneous or sequentially, whilst allowing continual re-arming to generate, regulate and diversify a sustained T-cell response over time.

Cell Therapy: Prescient has several other initiatives underway to develop new cell therapy approaches.

Targeted Therapies

PTX-100 is a first in class compound with the ability to block an important cancer growth enzyme known as geranylgeranyl transferase-1 (GGT-1). It disrupts oncogenic Ras pathways by inhibiting the activation of Rho, Rac and Ral circuits in cancer cells, leading to apoptosis (death) of cancer cells. PTX-100 is believed to be the



only RhoA inhibitor in the world in clinical development. PTX-100 is currently in a PK/PD basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. In a previous Phase 1 trial in advanced solid tumours, PTX-100 was well tolerated and achieved stable disease.

PTX-200 is a novel PH domain inhibitor that inhibits an important tumour survival pathway known as Akt, which plays a key role in the development of many cancers, including breast and ovarian cancer, as well as leukemia. Unlike other drug candidates that target Akt inhibition which are non-specific kinase inhibitors that have toxicity problems, PTX-200 has a novel mechanism of action that specifically inhibits Akt whilst being comparatively safer. This highly promising compound has encouraging Phase 2a data in HER2-negative breast cancer; Phase 1b/2 in relapsed and refractory AML and Phase 1b in recurrent or persistent platinum resistant ovarian cancer:

Find out more at ptxtherapeutics.com, or connect with us via Twitter [@PTX_AUS](https://twitter.com/PTX_AUS) and [LinkedIn](https://www.linkedin.com/company/ptxtherapeutics).

The Board of Prescient Therapeutics Limited have approved the release of this announcement.

For more information please contact:

Steven Yatomi-Clarke
CEO & Managing Director
Prescient Therapeutics
steven@ptxtherapeutics.com

Investor enquiries:
Warrick Lace – Reach Markets
+61 404 656 408
warrick.lace@reachmarkets.com.au

Media enquiries:
Andrew Geddes – CityPR
+61 2 9267 4511
ageddes@citypublicrelations.com.au

Disclaimer and Safe Harbor Statement

Certain statements made in this document are forward-looking statements within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These forward-looking statements are not historical facts but rather are based on the current expectations of Prescient Therapeutics Limited (“Prescient” or the “Company”), their estimates, assumptions, and projections about the industry in which Prescient operates. Material referred to in this document that use the words ‘estimate’, ‘project’, ‘intend’, ‘expect’, ‘plan’, ‘believe’, ‘guidance’, and similar expressions are intended to identify forward-looking statements and should be considered an at-risk statement. These forward-looking statements are not a guarantee of future performance and involve known and unknown risks and uncertainties, some of which are beyond the control of Prescient or which are difficult to predict, which could cause the actual results, performance, or achievements of Prescient to be materially different from those which may be expressed or implied by these statements. These statements are based on our management’s current expectations and are subject to a number of uncertainties and risks that could change the results described in the forward-looking statements. Risks and uncertainties include, but are not limited to, general industry conditions and competition, general economic factors, global pandemics and related disruptions, the impact of pharmaceutical industry development and health care legislation in the United States and internationally, and challenges inherent in new product development. In particular, there are substantial risks in drug development including risks that studies fail to achieve an acceptable level of safety and/or efficacy. Investors should be aware that there are no assurances that results will not differ from those projected and Prescient cautions shareholders and prospective shareholders not to place undue reliance on these forward-looking statements, which reflect the view of Prescient only as of the date of this announcement. Prescient is not under a duty to update any forward-looking statement as a result of new information, future events or otherwise, except as required by law or by any appropriate regulatory authority.

Certain statements contained in this document, including, without limitation, statements containing the words “believes,” “plans,” “expects,” “anticipates,” and words of similar import, constitute “forward-looking statements.” Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of Prescient to be materially different



from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the risk that our clinical trials will be delayed and not completed on a timely basis; the risk that the results from the clinical trials are not as favourable as we anticipate; the risk that our clinical trials will be more costly than anticipated; and the risk that applicable regulatory authorities may ask for additional data, information or studies to be completed or provided prior to their approval of our products. Given these uncertainties, undue reliance should not be placed on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the results of any revisions to any of the forward-looking statements contained herein to reflect future events or developments except as required by law.

This document may not contain all the details and information necessary for you to make a decision or evaluation. Neither this document nor any of its contents may be used for any other purpose without the prior written consent of the Company.

Supplemental COVID-19 Risk Factors

Please see our website : [Supplemental COVID-19 Risk Factors](#)